Using genetic testing to identify BRCA mutations in ovarian cancer can help inform the selection of frontline maintenance therapies and manage toxicities.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Home News Genetic Analysis Helps Maximize Clinical Benefit with PARP Inhibitors in BRCA+ Ovarian Cancer back to News
minute read
Using genetic testing to identify BRCA mutations in ovarian cancer can help inform the selection of frontline maintenance therapies and manage toxicities.
Topics: Press Coverage
1665 North Aurora Court
2004
Aurora, CO 80045
720-848-0300
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.